Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201000008I)
Received: 2 March 2020
Accepted: 6 October 2020
First Online: 6 November 2020
: Aspects of the described research have been filed for patent protection by three of the authors (G.A.S., G.E.P., and P.J.S.) and their home institutions (Northwestern University and the University of Nebraska). The title of the invention is: “Non-neuroinvasive viruses and uses thereof”. Two of the authors (G.A.S. and G.E.P.), have founded a company (Thyreos LLC) with the intention of developing live-attenuated viruses based on the findings described herein for the vaccine, oncolytic vector, and neural tracing vector applications. This does not alter their adherence to all policies on sharing data and materials. D.I.B. is a consultant to Merck and Genocea regarding herpes vaccines. He also serves on a DSMB for Moderna.